Valeo Pharma to Report Second Quarter 2021 Results and Hold Investors Conference Call / Webcast newswire.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswire.ca Daily Mail and Mail on Sunday newspapers.
Valeo Pharma Joins Innovative Medecines Canada
News provided by
Share this article
Valeo or the
Company ), a Canadian pharmaceutical company, today announced that Valeo has been accepted for admission into the Innovative Medicines Canada ( IMC ) Association as a full member. IMC has represented Canada s innovative pharmaceutical industry since 1914, with 47 members across the spectrum of small, mid-size and large national and multi-national companies. The association plays a central advocacy role in all major issues related to the pharmaceutical industry, including price reform. and the pan-canadian rare disease strategy, amongst others. IMC has also been playing an important role during the COVID-19 pandemic in supporting members and governments in the timely supply of vaccines and personal protective equipment. IMC has set guiding principles including its Code of Ethical Practices to promote ethics, respect and integrity in all interactions with stakeholders.
Valeo or the
Company ), a Canadian specialty pharmaceutical company, today announced that it has completed its negotiations and entered into a letter of intent ( LOI ) with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding Redesca® and Redesca HP®, its low molecular weight heparin ( LMWH ) biosimilar, for the prevention and treatment of thromboembolic disorders. The successful conclusion of negotiations with pCPA is a significant milestone delivered for the Redesca® commercialization program. We can now exchange with the provincial, territories and federal instances to ensure coverage under publicly funded drug plans in Canada , said Steve Saviuk, Valeo s CEO. While most prescriptions of LMWHs are initiated in the hospital, retail pharmacies play an important role in providing continued treatment to patients when they are discharged from hospital. Coverage by publicly funded drug plans are therefor a key component in making treatment available to Canadians .
Valeo Pharma Reports its First Quarter 2021 Results and Highlights newswire.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswire.ca Daily Mail and Mail on Sunday newspapers.
Valeo Pharma Announces Major Addition to its Senior Management Team
News provided by
Share this article
Steve Saviuk continues as CEO and becomes Vice-Chairman of the Board of Directors
MONTREAL, Jan. 18, 2021 /PRNewswire/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (
Valeo or the
Company ), a Canadian pharmaceutical company, announced today the appointment of Mr. Frederic Fasano to the newly created position of President and Chief Operating Officer, effective January 18th, to augment its senior leadership team and support expansion of Valeo s commercial activities. Mr. Fasano has also been elected to the Company s Board of Directors effective as of today.